GLYXAMBI supports ease of initiation
*Source: Fingertip Formulary, health plan or state listed below, and/or data on file, Boehringer Ingelheim Pharmaceuticals, Inc. as of 1/19/2019.

Streamline prior authorization (PA) for your practice
HubExpress offers dedicated support for providers who monitor the PA and proactively steps in to offer assistance where needed.
-
Keeps providers informed of PA status
-
Reduces paperwork and phone calls
-
Offers appeal assistance, if needed
-
Dedicated PA experts provide follow up
FAMILY†

Help your patients save with the GLYXAMBI savings card
Eligible Patients can pay as little as $0 per prescription for an entire year—and then re-enroll for another 12 months of savings after that, as long as they still qualify.
*Terms & Conditions:
Eligible patients 18 years or older may pay as little as $0/month with a maximum savings up to $400/monthly prescription. Card valid
for 12 consecutive months from activation date. Benefits not to exceed program expiration on December 31, 2019. If you live in
Massachusetts, card expires on the earlier of June 30, 2019, or date AB-rated generic equivalent is available. One card per patient, not
transferable, and cannot be combined with any other offer. Program not health insurance. Only valid for commercially insured patients
in the 50 United States, DC, and Puerto Rico. Not eligible if prescriptions are paid for in part/full by state or federally funded
program(s), like Medicare Part D, Medicaid, Vet. Aff., Dept. of Def., or TRICARE and where prohibited by law. Offer may change at any
time, without notice.
†As measured by TRx through 1/18/2019.
SGLT2i=sodium glucose co-transporter-2 inhibitor.
Frequently Asked Questions
What differentiates GLYXAMBI from other SGLT2 inhibitor-based FDCs?
GLYXAMBI is the only fixed-dose combination (FDC) that contains Jardiance® (empagliflozin), the #1 prescribed sodium glucose co-transporter-2 inhibitor (SGLT2i)*, in combination with Tradjenta® (linagliptin), a DPP-4 inhibitor.
*As measured by NBRx from 7/27/18 to 1/18/19.
DPP-4=dipeptidyl peptidase-4.
How can treatment with GLYXAMBI benefit my patients?
In the GLYXAMBI trial in patients with type 2 diabetes who were inadequately controlled on at least 1500 mg of metformin, patients treated with GLYXAMBI experienced a significant reduction in A1C from baseline at 24 weeks vs the individual components. In the EMPA-REG OUTCOME Trial, Jardiance® (empagliflozin), which is a component of GLYXAMBI, significantly reduced the risk of CV death in adults with type 2 diabetes and established CV disease on top of standard of care CV and type 2 diabetes medications. The effectiveness of GLYXAMBI on reducing the risk of CV death in adults with type 2 diabetes and CV disease has not been established.
Can my patients take GLYXAMBI with other type 2 diabetes medications?
In the GLYXAMBI trial in patients with type 2 diabetes who were inadequately controlled on at least 1500 mg of metformin, patients continued to receive metformin throughout the trial.
What is the indication for GLYXAMBI?
GLYXAMBI contains Jardiance® (empagliflozin), a sodium glucose co-transporter-2 inhibitor (SGLT2i), and Tradjenta® (linagliptin), a DPP-4 inhibitor. GLYXAMBI is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both empagliflozin and linagliptin is appropriate.
JARDIANCE, a component of GLYXAMBI, is indicated to reduce the risk of cardiovascular (CV) death in adults with type 2 diabetes mellitus and established CV disease. The effectiveness of GLYXAMBI on reducing the risk of CV death in adults with type 2 diabetes and CV disease has not been established.
GLYXAMBI is not recommended for patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.
DPP-4=dipeptidyl peptidase-4.
What are the components of GLYXAMBI?
GLYXAMBI is a combination of Jardiance® (empagliflozin), a sodium glucose co-transporter-2 inhibitor (SGLT2i), and Tradjenta® (linagliptin), a DPP-4 inhibitor. Only GLYXAMBI contains JARDIANCE, the #1 prescribed SGLT2i* together with lingaliptin.
*As measured by NBRx from 7/27/18 to 1/18/19.
DPP-4=dipeptidyl peptidase-4.
What are the common side effects of GLYXAMBI?
The most common adverse reactions associated with GLYXAMBI (a 5% or greater incidence) were urinary tract infections, nasopharyngitis, and upper respiratory tract infections.
Please see Important Safety Information and full Prescribing Information for a more detailed description of safety.
When should I prescribe GLYXAMBI?
You can prescribe GLYXAMBI as an adjunct to diet and exercise for adults with type 2 diabetes who need glycemic control and may benefit from treatment with Jardiance® (empagliflozin) and Tradjenta® (linagliptin) in a single pill taken once a day.
What is the recommended dosage for GLYXAMBI?
The recommended dose of GLYXAMBI is 10 mg empagliflozin/5 mg linagliptin once daily in the morning, taken with or without food. In patients tolerating GLYXAMBI, the dose may be increased to 25 mg empagliflozin/5 mg linagliptin once daily.
Assessment of renal function is recommended prior to initiation of GLYXAMBI and periodically thereafter. GLYXAMBI should not be initiated in patients with an eGFR less than 45 mL/min/1.73 m2. No dose adjustment is needed in patients with an eGFR greater than or equal to 45 mL/min/1.73 m2.
Is there a Savings Card program for GLYXAMBI?
Yes. The Jardiance® (empagliflozin) Family Savings Card* can provide savings for all JARDIANCE Family medications, including GLYXAMBI. The Family Savings Card can help your eligible patients who are 18 years or older get their medication for as little as $0 per month for 12 consecutive months, with a maximum savings of up to $400 per monthly prescription. Your patients who currently have the GLYXAMBI Card can continue to use it for savings and will be enrolled in the JARDIANCE Family Savings Card program. One year after their original enrollment in the savings program, they will receive a notification to re-enroll in the JARDIANCE Family Savings Card program.
*Terms & Conditions: Eligible patients 18 years or older may pay as little as $0/month with a maximum savings up to $400/monthly prescription. Card valid for 12 consecutive months from activation date. Benefits not to exceed program expiration on December 31, 2019. If you live in Massachusetts, card expires on the earlier of June 30, 2019, or date AB-rated generic equivalent is available. One card per patient, not transferable, and cannot be combined with any other offer. Program not health insurance. Only valid for commercially insured patients in the 50 United States, DC, and Puerto Rico. Not eligible if prescriptions are paid for in part/full by state or federally funded program(s), like Medicare Part D, Medicaid, Vet. Aff., Dept. of Def., or TRICARE and where prohibited by law. Offer may change at any time, without notice.
What type of coverage does GLYXAMBI have?
GLYXAMBI is covered for nearly 80% of commercial patients.*
*Source: Fingertip Formulary, health plan or state listed above, and/or data on file, Boehringer Ingelheim Pharmaceuticals, Inc. as of 1/19/2019. Placement on formulary does not establish clinical comparability of products, including safety and efficacy, and is not a guarantee of full or partial coverage and/or payment. Contact health plan, state, or www.medicare.gov for most current information, as it may change without notice.